StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.73+0.01 (+0.58%)

Close on Nov 18, 2026Market cap $36.39MP/E –Yield –

Grace Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2021CQ2 2020Jun 30, 2020-$4.21M–
Q4 FY2020CQ1 2020Mar 31, 2020-$23.26M–
Q1 FY2020CQ2 2019Jun 30, 2019-$6.84M–
Q4 FY2019CQ1 2019Mar 31, 2019-$25.32M–

More Grace Therapeutics figures

See a number that looks wrong?